Monitoring of Minimal Residual Disease After Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia Allows for the Identification of Impending Relapse: Results of the ALL-BFM-SCT 2003 Trial
Peter Bader(Goethe University Frankfurt), Christina Peters(Cancer Research Institute of the Slovak Academy of Sciences), Hermann Kreyenberg(Friedrich-Alexander-Universität Erlangen-Nürnberg), Ingo Müller(Universität Hamburg), Julia Alten(Christian-Albrechts-Universität zu Kiel), Martin Schrappe(University Hospital Schleswig-Holstein), Ansgar Schulz(University Hospital Ulm), Michael H. Albert(LMU Klinikum), André Schrauder(University Hospital Schleswig-Holstein), André Willasch(Goethe University Frankfurt), Roland Meisel(Düsseldorf University Hospital), Peter Lang(STZ eyetrial), Arend von Stackelberg(Charité - Universitätsmedizin Berlin), Cornelia Eckert(Humboldt-Universität zu Berlin), Emilia Salzmann‐Manrique(Goethe University Frankfurt), Thomas Klingebiel(Goethe University Frankfurt), Ulrike Pöetschger(Friedrich-Alexander-Universität Erlangen-Nürnberg), Daniel Stachel(Friedrich-Alexander-Universität Erlangen-Nürnberg)
Cited by 132
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase–mediated tryptophan degradation
|Blood|2004|1.6k
Rational Extended Thermodynamics
|Springer Tracts in Natural Philosophy|1998|1.3k
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
|Journal of Clinical Oncology|2015|1k